In Nukus, Karakalpakstan, in the west of Uzbekistan, MSF officially launched the tuberculosis (TB) PRACTECAL clinical trial in December. The first patients will begin treatment in January 2017.
The trial combines the first new TB drugs available in over 50 years with existing drugs to treat drug-resistant forms of the disease. Uzbekistan is among the top 27 countries with the highest rates of multidrug-resistant TB (MDR-TB).
In July, MSF began treating children with a shorter regimen of nine months, instead of the usual 12 months or more, and is conducting research into the results. At the end of December 2016, eight children were on the shorter treatment. The medical outcomes for adults on the shorter treatment will be published at the end of 2017. These initiatives are part of MSF’s drive to develop shorter, more tolerable treatment regimens for people suffering from TB.
MSF runs all its TB projects in collaboration with the regional and central ministries of health. These long-standing relationships have enabled MSF to develop a model of care that for some patients combines outpatient care with a state of the art diagnostic test, GeneXpert, and a comprehensive support programme. Where possible, this allows them to be treated in their homes from day one. In 2016, over 2,640 patients started TB treatment on this programme; 1,767 were treated for drug-sensitive TB and 878 for drug-resistant TB. SIxty-three patients were on treatment for extensively drug-resistant TB and 49 were treated with new drugs: 29 were started on bedaquiline, linezolid and imipenem, 12 on bedaquiline and linezolid, and eight on linezolid and the conventional regimen.
In the capital, Tashkent, MSF supports the regional AIDS centre, with the aim of increasing access to diagnosis and care for patients living with HIV and treating co-infections. In 2016, 25 patients started treatment for hepatitis C, and for the first time in Uzbekistan, 13 patients were initiated on third-line antiretroviral (ARV) treatment for HIV, after their initial and subsequent treatments ceased to work. In total, 842 patients started ARV treatment in 2016.
Year MSF first worked in the country: 1997.
|No. staff in 2016||248|
|2016 Expenditure||€9.8 million|
- Extensively drug-resistant tuberculosis (XDR-TB)Apply Extensively drug-resistant tuberculosis (XDR-TB) filter (4)
- HIV/AIDSApply HIV/AIDS filter (2)
- Infectious diseasesApply Infectious diseases filter (43)
- MalariaApply Malaria filter (2)
- Multidrug-resistant tuberculosis (MDR-TB)Apply Multidrug-resistant tuberculosis (MDR-TB) filter (10)
- Parasitic diseasesApply Parasitic diseases filter (2)
- Sleeping sickness (human African trypanosomiasis)Apply Sleeping sickness (human African trypanosomiasis) filter (1)
- TuberculosisApply Tuberculosis filter (43)
- 2017Apply 2017 filter (2)
- 2016Apply 2016 filter (1)
- 2015Apply 2015 filter (2)
- 2013Apply 2013 filter (2)
- 2012Apply 2012 filter (1)
- 2011Apply 2011 filter (30)
- 2010Apply 2010 filter (3)
- 2008Apply 2008 filter (1)
- 2005Apply 2005 filter (2)
- 2003Apply 2003 filter (3)
- 2002Apply 2002 filter (1)
- 2001Apply 2001 filter (1)
- 2000Apply 2000 filter (1)
- 1998Apply 1998 filter (1)